Tirzepatide
Also known as: Mounjaro, Zepbound, Tirzepatid, Tirze, Dual Agonist
Dual agonist acting on two gut hormone receptors at once — more effective for weight loss than semaglutide, and often better tolerated at comparable results.
Substance family
Gut hormone analogues that suppress appetite. Highly effective for fat loss, with the consistent caveat that a substantial share of the weight lost is lean mass unless protein and training compensate.
Effects on
Which outcomes this substance acts on — descriptive, not a recommendation.
Strain profile
Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.
This substance causes
This substance works against
Dosing & protocols by goal
Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.
Obesity / diabetes (approved schedule)
MedicalDose
2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg / week
Frequency
1× / week, subcutaneous
Cycle length
Each step held for at least 4 weeks
2.5 mg is a starting dose for tolerability, not a therapeutic one. Most of the effect appears from 5 mg upwards.
Diet phase in a bodybuilding context
IntermediateDose
2.5–7.5 mg / week
Frequency
1× / week, subcutaneous
Cycle length
8–16 weeks
The lower steps are usually sufficient. Higher doses suppress intake to a point where hitting protein targets becomes the limiting problem.
Off-season appetite control
IntermediateDose
2.5–5 mg / week
Frequency
1× / week, subcutaneous
Cycle length
Varies
Enough to keep appetite manageable without noticeably compromising training performance.
Side effect & countermeasure
Typical problems and what you can do to reduce harm — at a glance. Does not replace medical monitoring.
Problem
Loss of lean mass alongside fat
Countermeasure
Because tirzepatide produces greater total weight loss than semaglutide, the absolute amount of muscle at risk is correspondingly larger. Protein at roughly 2–2.5 g per kg of body weight, resistance training throughout, moderate deficit. Track body composition rather than scale weight.
Problem
Nausea, vomiting, constipation when increasing the dose
Countermeasure
Generally milder than with semaglutide at comparable weight loss, but present. Hold each step for at least four weeks; if a step is poorly tolerated, stay on it longer rather than moving up.
Problem
Delayed gastric emptying
Countermeasure
As with all agonists in this class. Inform the anaesthetist before any procedure requiring anaesthesia — a full stomach is an aspiration risk. Severe persistent vomiting needs medical assessment.
Problem
Hypoglycaemia when combined with insulin or sulfonylureas
Countermeasure
Relevant for anyone with diabetes: the dual mechanism lowers blood glucose more strongly than GLP-1 alone. Combination therapy requires medical dose adjustment, not self-management.
Problem
Dehydration and electrolyte shifts
Countermeasure
Lower food intake means less fluid and fewer electrolytes. Drink deliberately, keep sodium and potassium adequate.
Problem
Weight regain after stopping
Countermeasure
Appetite returns on discontinuation. Taper the dose and establish eating habits during use rather than relying on the substance.
Problem
Uncertain quality of grey-market product
Countermeasure
Only sources with an independent analysis certificate; reconstitute sterile, store refrigerated, observe the labelled shelf life.
Overview
Tirzepatide is the successor generation to semaglutide and works on two receptors at once instead of one. In the head-to-head trials that compared them directly, it produced greater weight loss — and did so with a side-effect profile that was, if anything, somewhat easier to tolerate.
For fat-loss purposes it is currently the most effective approved option. Everything that applies to semaglutide regarding muscle loss applies here too, and in absolute terms more so, because the total weight loss is larger.
Mechanism of Action
Tirzepatide activates both the GLP-1 receptor and the GIP receptor. GIP is a second gut hormone that, like GLP-1, is released after eating and influences insulin secretion and fat metabolism.
The combination of the two appears to be more than the sum of its parts. GLP-1 alone suppresses appetite and slows gastric emptying — with the gastrointestinal side effects that follow. The additional GIP activity contributes to metabolic effects and appears to reduce the nausea that GLP-1 activation produces. This is the reason tirzepatide is often better tolerated despite its stronger effect.
The half-life of around five days permits weekly injection. The titration principle is the same as with semaglutide: each step held for at least four weeks, since tolerability depends on how quickly the dose rises.
Typical Context
In the bodybuilding context, tirzepatide is used in diet phases and for off-season appetite control. Doses generally stay in the lower steps — two and a half to seven and a half milligrams — because the higher approved doses suppress food intake so effectively that protein targets become difficult to hit.
That is the recurring theme in this class of substance and worth stating plainly: the constraint is not the weight coming off. The constraint is keeping enough muscle while it does. A substance that removes appetite removes the mechanism that normally corrects insufficient intake, which means protein has to be scheduled rather than eaten by inclination.
The stronger effect relative to semaglutide has a practical implication that is easy to miss. Greater weight loss over the same period means a larger deficit, and a larger deficit means a greater share of lean mass at risk unless training and protein compensate.
Side Effects & Risks
- Loss of lean mass alongside fat, in absolute terms greater than with semaglutide
- Nausea, vomiting, constipation or diarrhoea, especially when increasing the dose
- Delayed gastric emptying
- Hypoglycaemia when combined with insulin or sulfonylureas
- Dehydration and electrolyte shifts
- Reduced training performance at higher doses
- Gallstones with rapid weight loss
- Rarely: pancreatitis
Blood Work & Monitoring
- HbA1c and fasting glucose — the dual mechanism lowers glucose more strongly than GLP-1 alone
- Body composition — the key measurement; scale weight hides muscle loss
- Electrolytes (sodium, potassium)
- Lipid profile (LDL, HDL, triglycerides) — usually improves with weight loss
- Liver values (ALT, AST, GGT)
Harm-Reduction Notes
- Protein has to be planned, not eaten by feel — around 2–2.5 g per kg of body weight
- Keep resistance training running throughout; it is the main protection against muscle loss
- Stay in the lower dose steps unless there is a specific reason to go higher
- Hold each titration step for at least four weeks
- Inform the anaesthetist before any procedure — delayed gastric emptying is an aspiration risk
- With diabetes medication, dose adjustment belongs with a doctor
- Track body composition, not scale weight alone
- Plan the exit deliberately; appetite returns on discontinuation
Legal status by region
Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.
| Region | Regulatory status |
|---|---|
| United States | Prescription-only medicineApproved for defined indications; use outside them is off-label. |
| EU / UK | Prescription-only medicineApproved for defined indications. |
| Canada / Australia | Prescription-only medicine |
| Parts of Asia, Latin America & Middle East | Pharmacy availability variesSeveral countries dispense it without prescription in practice. Rules and enforcement differ and change. |
| Competitive sport | Check the current WADA listSome substances in this class are prohibited, others are not. |